FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2023

SHINTO ORGANICS PRIVATE LIMITED

(FORMERLY KNOWN AS SHINTO BIOTEC LIMITED)

CIN: U24231CH1994PTC015041

AUDITORS

AVNISH SHARMA & ASSOCIATES

CHARTERED ACCOUNTANTS

PANCHKULA & CHANDIGARH

E-MAIL: asachditr@gmail.com PHONE: 0172-3500880/81 CELL: 9872980396/9888438628

AVNISH SHARMA & ASSOCIATES

CHARTERED ACCOUNTANTS

#49, SUSHILA VILLA, SECTOR 7, PANCHKULA, HARYANA-134109 SCO 39, FF, SECTOR 20-C, DAKSHIN MARG, CHANDIGARH, 160020

Phone no.: (O) 0172-3500880/81 (M) 9872980396

E-mail: avnishca@hotmail.com

MSME Reg. No. UDYAM-CH-01-0010088



INDEPENDENT AUDITOR'S REPORT

To the members of SHINTO ORGANICS PRIVATE LIMITED Report on the Financial Statements

Opinion

We have audited the accompanying financial statements of M/s SHINTO ORGANICS PRIVATE LIMITED ("the Company"), which comprises the Balance Sheet as at 31st March, 2023, the Statement of Profit and Loss and statement of cash flows for the year then ended and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023, and profit and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information other than the Financial Statements and Auditor's Report thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibility of Management for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2021. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgements and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of these financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.



Auditor's Responsibility for the Audit of Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

As required by Section 143(3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.
- (b) In our opinion, proper books of accounts as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2021.



- (e) On the basis of the written representations received from Directors as on 31st March, 2022 taken on record by the Board of Directors, none of the Directors is disqualified as on 31st March, 2022 from being appointed as a Director in terms of Section 164(2) of the Act.
- (f) Since the Company's turnover as per last audited financial statements is less than Rs. 50 Crores and its borrowings from banks and financial institutions at any time during the year is less than Rs. 25 Crores, the Company is exempted from getting an audit opinion with respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls vide notification dated June 13, 2017;
- (g) With respect to the other matters to be included in the Auditor's report in accordance with the requirements of Sec 197(16) of the Act as amended, we report that Section 197 is not applicable to a private company. Hence reporting as per Section 197(16) is not required.
- (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2021, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position;
 - ii. The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses;
 - iii. There were no amounts which required to be transferred by the Company to the Investor Education and Protection Fund.

iv. The Management has represented that, to the best of it's knowledge and belief, as disclosed in the note 23(r) to the financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the "Ultimate Beneficiaries".

v.The Management has represented, that, to the best of it's knowledge and belief, as disclosed in the note 23(r) to the standalone financial statements, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

vi.Based on such audit procedures performed as considered reasonable and appropriate in the circumstances, nothing has come to our attention that causes us to believe that the management representations under sub-clauses (a) and (b) above contain any material misstatement;

vii. The company has not proposed any dividend under Section 123 of Companies Act, 2013.

viii. Proviso to rule 3(1) of the Companies (Accounts) Rules 2021 for maintaining books of accounts using accounting software which has feature of recording audit trail (edit log) facility is applicable to the Company with effect from April 1,2022, and accordingly reporting under Rule 11(g) of the Companies (Audit & Auditors) Rules 2021 is not appliable for the financial year ended March 31,2023.

As required by the Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government of India in terms of sub-sectiom (11) of Section 143 of the Companies Act, 2013 we give in 'Annexure A' a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

For Avnish Sharma & Associates Chartered Accountants

FRN - 009398N

MEGHA GOEL M. NO. 529746

(Partner)

UDIN: 23529746BHADWI8839

Place: Chandigarh Dated: 07.07.2023

ANNEXURE 'A' TO THE INDEPENDENT AUDITOR'S REPORT

(Referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Reports on Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government in terms of Section 143 (11) of the Companies Act, 2013 ('the Act') of Megastar Foods Limited ('the Company')

- (i) (a) The company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant & Equipment on the basis of available information.
 - (b) The company, during the year under consideration, did not own any intangible asset.
 - (b) As explained to us, the Property, Plant and Equipment of the Company have been physically verified by the management at reasonable intervals. According to the information and explanation given to us by the management, no material discrepancies have been noticed on such verification.
 - (c) The title deeds of immovable properties are held in the name of the company.
 - (d) The Company has not revalued its property, plant and equipment during the year ended March 31, 2023.
 - (e) As explained to us, no proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transaction (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.
- (ii) (a) Physical verification of inventory has been conducted at reasonable intervals by the management and in our opinion, the coverage and procedure of such verification by the management is appropriate. No discrepancies of 10% or more in the aggregate for each class of inventory were noticed during such verification.
 - (b) During the year, the company has not been sanctioned working capital limits on the basis of security of current assets.
- (iii) (a) During the year, the Company has not granted fresh loans or advances in the nature of loans, stood guarantee or provided security or made investment to any party.
 - (b) During the year neither any fresh investments were made, nor any guarantees were provided. The terms and conditions of the old investments and loans provided are not prejudicial to the Company's interest.
 - (c) The outstanding loans are being served as per terms & conditions and interest is recovered & there is no overdue payment.
 - (d) The outstanding loans have no overdue payments.
 - (e) The loans or advances which have fallen due during the year are not being renewed/extened.
 - (f) The Company has not granted any loans or advances in the nature of loans, either repayable on demand or without specifying any terms or period of repayment to companies, firms, Limited Liability Partnerships or any other parties. Accordingly, the requirement to report on clause 3(iii)(f) of the Order is not applicable to the Company.
- (iv) In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of Section 185 and 186 of the Act in respect of grant of loans, making investments and providing guarantees and securities, as applicable.
- (v) In our opinion and according to the information and explanations given to us, the Company has neither accepted any deposits from the public nor accepted any amounts which are deemed to be deposits within the meaning of sections 73 to 76 of the Companies Act and the rules made thereunder, to the extent applicable. Accordingly, the requirement to report on clause 3 (v) of the Order are not applicable to the Company.
- (vi) As informed to us, the maintenance of cost records has not been specified by the Central Government under section 148(1) of the Companies Act, 2013 for the business activities carried out by the Company. Thus reporting under clause 3(vi) of the order is not applicable to the Company.
- (vii) According to the information and explanations given to us, in respect of statutory dues:
 - (a) The Company has generally been regular in depositing undisputed statutory dues, including Income Tax, Sales Tax, Service Tax, Value Added Tax, duty of Customs, duty of Excise, Cess and other material statutory dues applicable to it with the appropriate authorities.
 - (b) There were no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, Customs Duty, Excise Duty, Value Added Tax, Cess and other material statutory dues in arrears as at 31st March, 2022 for a period of more than six months from the date they became payable.



- (viii) According to the records of the company examined by us and as per the information and explanation given to us, there were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).
- (ix) (a) According to the records of the company examined by us and as per the information and explanations given to us, the company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any financial institution or banks or lender.
 - (b) According to the records of the company examined by us and as per the information and explanations given to us, The Company has not been declared willful defaulter by any bank or financial institution or government or any government authority.
 - (c) According to the records of the company examined by us and as per the information and explanations given to us, the term loans were applied for the purpose for which the loans were obtained.
 - (d) According to the records of the company examined by us and as per the information and explanations given to us, on an overall examination of the financial statements of the Company, no funds raised on short-term basis have been used for long-term purposes by the Company.
 - (e) The company has no subsidiary, hence clause 3(ix)(e) & (f) are not applicable to the company.
- (x) (a) According to the information and explanations given to us and based on our examination of the records of the company, the Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause 3(x)(a) of the Order is not applicable.
 - (b) The Company has not made any preferential allotment or private placement of shares /fully or partially or optionally convertible debentures during the year under audit. Accordingly, the requirement to report on clause 3(x)(b) of the Order is not applicable to the Company.
- (xi) (a) According to the information and explanations given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit.
 - (b) No report under Section 143(12) of the Act has been filed with the Central Government for the period covered by our audit.
 - (c) According to the information and explanations given to us, during the year there are no whistle blower complaints received by the company during the year.
- (xii) The Company is not a Nidhi Company and hence reporting under clause 3(xii) of the Order is not applicable.
- (xiii) In our opinion and according to the information and explanations given to us, the Company is in compliance with Section 177 and 188 of the Act, where applicable, for all transactions with related parties and the details of related party transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- (xiv) (a) In our opinion the Company has its own internal audit system ,which needs to be strengthened to commensurate with the size and the nature of its business.
- (xv) In our opinion during the year the Company has not entered into any non-cash transactions with its directors or persons connected with its directors. Hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.
- (xvi) (a) In our opinion, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi)(a), (b) and (c) of the Order is not applicable.
 - (b) According to the information and explanations given to us and based on our examination of the records of the company, the Company has not conducted any Non-Banking Financial or Housing Finance activities without obtained a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934.
 - (c) According to the information and explanations given to us and based on our examination of the records of the company, the Company is not a Core Investment Company as defined in the regulations made by Reserve Bank of India. Accordingly, the requirement to report on clause 3(xvi) (c) of the Order is not applicable to the Company.



- (d) In our opinion, there is no core investment company within the Group (as defined in the Core InvestmentCompanies (Reserve Bank) Directions, 2016) and accordingly reporting under clause 3(xvi)(d) of the Order is not applicable.
- (xvii) The company has not incurred cash losses in the financial year and not in the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors during the year. Accordingly, reporting under Clause 3(xviii) of the Order is not applicable to the Company.
- There are no material uncertainty on the date of the audit report on an evaluation of: The ageing report, financial ratios and expected dates of realisation of financial assets and payment of financial liabilities, any other information accompanying the financial statements, the auditor's knowledge of the Board of Directors and management plans. The company can meet its the liabilities which exist as at the balance sheet date when such liabilities are die in the future.
- (xx) The provisions of Section 135 relating to Corporate Social Responsibility (CSR) does not apply to company for the year under consideration and hence reporting under clause 3(xx) of the Order is not applicable.
- (xxi) There have been no qualifications or adverse remarks in the audit reports issued by the respective auditors in case of companies included in the consolidated financial statements.

For Avnish Sharma & Associates Chartered Accountants

FRN - 009398N

MEGHA GOEL M. NO. 529746

(Partner)

UDIN: 23529746BHADWI 8839

Place : Chandigarh

Dated: 07.07.2023

SHINTO ORGANICS PRIVATE LIMITED (FORMERLY KNOWN AS SHINTO BIOTEC LIMITED)

CIN: U24231CH1994PTC015041 BALANCE SHEET AS AT 31ST MARCH, 2023 AMOUNT IN ₹00

BALANCE SHEET AS AT 31ST MARCH, 2023				
	Note No.		AS AT 31ST	
PARTICULARS		MARCH, 2023	MARCH, 2022	
		1		
EQUITY AND LIABILITIES		1		
1 Shareholders' Funds	,	25,000.00	25,000.00	
(a) Share Capital	3 4	253,170.49	249,426.28	
(b) Reserves And Surplus	49	233,170.45		
(c) Money received against share warrants				
2 Share application money pending allotment		-	-	
3 Non-Current Liabilities	_	96,707.46	106,257.6	
(a) Long-Term Borrowings	5	90,707		
(b) Deferred Tax Liabilities (Net)		1 . /		
(c) Other Long term liabilities		. '	í -	
(d) Long term provisions		1		
4 Current Liabilities		9,550.16	8,892.9	
(a) Short Term borrowings	6	9,550.10	0,000	
(h) Trade Payables	7	,		
1 Total outstanding dues of micro enterprises and small enterprises		-	-	
2 Total outstanding dues of creditors other than micro enterprises and small enterprises		220,094.41	244,277.	
and the state of t	8	59,177.62		
(c) Other Current Liabilities	9	0.00	-	
(d) Short Term Provisions		663,700.14	642,575	
тот	AL	663,700.14	042,0.2	
I. ASSETS	**			
1 Non-Current Assets				
(a) Property, Plant & Equipments	10	40,515.53	48,722	
(a) Tangible Assets				
(b) Intangible Assets				
(b) Non -Current Investment		235.86	89	
(c) Deferred Tax Assets (Net)				
(d) Long term loans & advances		-		
(e) Other Non-Current Assets				
2 Current assets		_		
(a) Current Investment	11	235,984.26	203,863	
(b) Inventories	12	376,465.33		
(c) Trade Receivables	13	4,642.81	The second secon	
(d) Cash And Cash Equivalents	14	5,856.35		
(e) Short Term Loans And Advances	14	-		
(f) Other Current Assets				
то	ΓAL	663,700.14	4 642,57	
Significant Accounting Policies	1-2			
Notes on Financial Statements	23			

As per our report of even date attached For Avnish Sharma & Associates

Chartered Accountants

FRN - 009398N CHARTERED CHARTERED CHARTERED

MEGHA GOEL M. NO. 529746

(Partner)
UDIN: 23 519746 BHADW I 8839
Place: Chandigarh

Dated: 07.07.2023

For & on behalf of the Board SHINTO ORGANICS PRIVATE LIMITED

HARSH GULATI MG. DIRECTOR DIN: 00986687

USHA GULATI DIRECTOR

DIN: 00986683

SHINTO ORGANICS PRIVATE LIMITED (FORMERLY KNOWN AS SHINTO BIOTEC LIMITED)

CIN: U24231CH1994PTC015041

AMOUNT IN ₹00

STATEMENT OF PROFIT & LOSS FOR THE PERIOD 01.04.2022 TO 31.03.2023

PARTICULARS	Note No.	For the year as on 31st March , 2023	For the year as on 31st March, 2022
Income: I Revenue from operations Other income III. Total Inome	15 16	566,937.05 122.10 567,059.15	506,229.28 146.50 506,375.78
IV. Expenses: Purchases Changes in inventories of Stock in Trade Employee Benefits Expense Financial Cost Depreciation And Amortization Expense Other Expenses Total Expenses	17 18 19 20 21 22	464,227.68 (32,122.30) 75,529.75 8,107.89 8,206.75 38,049.09 561,998.87	365,827.01 (4,376.25 72,644.49 8,843.58 8,886.07 41,092.00
V. Prior Period Expenses		-	-
VI Profit Before tax VII Tax Expense: Current Tax Mat Credit Deferred Tax Expense/(Income) Profit After Tax VIII Earnings Per Equity Share: (1) Basic (In absolute figures) (2) Diluted (In absolute figures)		5,060.28 1,419.86 - (146.29) 3,786.71 1.51 1.51	13,458.88 3,383.21 - 67.22 10,008.49 4.00 4.00
Significant Accounting Policies Notes on Financial Statements	1-2 23		

As per our report of even date attached

For Avnish Sharma & Associates

Chartered Accountants

199 CHARTERED

FRN - 009398N (

MEGHA GOEL M. NO. 529746

(Partner)

UDIN: 2352 9746 BHADWI 8839 Place: Chandigarh

Dated: 07.07.2023

For & on behalf of the Board SHINTO ORGANICS PRIVATE LIMITED

HARSH GULATI MG. DIRECTOR

DIN: 00986687

USHA GULATI DIRECTOR

DIN: 00986683

SHINTO ORGANICS PRIVATE LIMITED (FORMERLY KNOWN AS SHINTO BIOTEC LIMITED) CASH FLOW STATEMENT FOR THE YEAR ENDED 31.03.2023

	5.060.28		13,458.88
	3,000.20		20,100.00
8 206 75	1	8 886 07	
8,200.75		0,000.07	
_			
7 945 59		8 362 38	
7,545.55		0,302.30	
87.10		146.50	
67.10		140.50	
-	16 065 24		17,101.95
	16,065.24		17,101.55
	21,125.52		30,560.83
(3,614)		16,401.91	
(32,122.30)	9.9	(4,376.25)	
1,396.87		884.23	
	-34,339.64	-	12,909.89
(24,183.48)	ĺ	(21,487.87)	
50,456.53	26,273.05	(5,782.34)	-27,270.21
_	43.050.03	_	46 200 54
			16,200.51 3,383.21
	(2)		3,363.21
	An-management in		0.262.20
	7,945.59		8,362.38
	3,650.93		4,454.92
-		(235)	
-		-	
87.10		146.50	
	87.10		-88.50
(0.550.22)		4 096 38	
		4,030.30	
037.18			
	(8,893.05)		4,096.38
	(5,154.97)		8,462.80
	i		
	0.707		4 224 22
	9,797.77 (5,154.97)		1,334.98 8,462.80
	(32,122.30) 1,396.87 (24,183.48) 50,456.53	7,945.59 87.10 -	8,206.75 7,945.59 8,362.38 87.10 16,065.24 21,125.52 (3,614) (32,122.30) 1,396.87 - 34,339.64 (24,183.48) 50,456.53 26,273.05 13,058.93 1,419.86 42.50 7,945.59 3,650.93 87.10 87.10 (9,550.23) 657.18 (8,893.05)

- 1. The above 'Cash Flow Statement' has been prepared under the indirect method as set out in accounting standard-3 Cash Flow Statements.
- 2. Figures in bracket indicate cash outflow
- 3. Previous year figures have been regrouped and recasted whereever necessary to conform to the current year figures.
- 4. The Cash Flow Statement for the year has been prepared by Rounding off to Rs. Hundreds in compliance with Schedule III of the Companies Act, 2013.

For Avnish Sharma & Associates

Chartered Accountants

MEGHA GOFL M. NO. 529746

(Parther)
UDIN-235299196BHADWI8839
Place: Chandigarh

Dated: 07.07.2023

For & on behalf of the Board SHINTO ORGANICS PRIVATE LIMITED

MG. DIRECTOR DIRECTOR DIN: 00986687 DIN: 00986683

HARSH GULATI USHA GULATI

SHINTO ORGANICS PRIVATE LIMITED

(FORMERLY KNOWN AS SHINTO BIOTEC LIMITED)

Significant Accounting Policies and Notes forming part of the Financial Statements Year Ended: 31-March-2023

COMPANY OVERVIEW

Shinto Organics Private Limited (Formerly known as Shinto Biotec Limited) is in the business of wholesale trading of Pharmaceutical Products. The Company was incorporated on 7th September 1994 under the Companies Act, 1956. The company has its Registered Office at 1358, Sector 22-B, Chandigarh and Head Office at 110, Industrial Area, Phase II, Panchkula.

SIGNIFICANT ACCOUNTING POLICIES

a) Basis of preparation of Financial Statements:

These financial statements have been prepared under historical cost convention on the accrual basis of accounting, in accordance with the Generally Accepted Accounting Principles in India ('Indian GAAP') to comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and the relevant provisions of the Companies Act, 2013

The accounting policies adopted in the preparation of the financial statements are consistent with those of the previous year.

b) Use of estimates:

The preparation of financial statements requires estimates and assumptions to be made that affect the reported amount of assets and liabilities (including contingent liabilities) on the date of financial statements and the reported amount of revenue and expenses, during the reported period. Actual results could differ from those estimates.

c) Property, Plant & Equipments

Property, Plant & Equipments are stated at cost of acquisition inclusive of inward freight, duties, taxes and incidental expenses related to acquisition but net of duty credit availed. All pre-operative expenditure including interest on borrowings, specifically for the acquisition/project or interest on general borrowings to the extent utilized for such project, for the period up to the completion of erection is capitalized as part of the asset cost. Indirect expenditure related to acquisition & erection of machineries for the period up to the completion of such erection is treated as pre-operative expenditure and allocated on pro-rata basis.

d) Depreciation/Amortisation

Depreciation has been provided on straight line method on the economic useful life prescribed by Schedule II to the Companies Act, 2013. Depreciation on additions to or disposal of assets is calculated on pro-rata basis.

Type of Asset	Period
Plant & Machinery	15 years
Electrical Equipments	10 years
Furniture & Fixtures	10 years
Car	8 years
Mobile	5 years
Water Cooler	5 years
Computer	3 years

e) Impairment

The immovable fixed assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is treated as impaired when its carrying amount exceeds its recoverable amount. The impairment is recognised by debiting the profit & loss account and is measured as the amount by which the carrying amount of the impaired assets exceeds their recoverable value.

f) Revenue Recognition

Revenues from the sale of Pharmaceuticals are recognised upon delivery, which is when title passes to the

Interest and Other Income is recognised on accrual basis.

g) Borrowing Cost:

Borrowing cost attributable to acquisition of qualifying fixed assets which takes substantial period of time to get ready for its intended use is capitalised as part of the cost of such fixed assets. All other borrowing costs are charged to revenue.



h) Taxation:

Provision for income tax is made in accordance with provisions of the Income Tax Act, 1961. Deferred tax liabilities and assets are recognized at substantively enacted tax rates. Subject to the consideration of prudence, on timing difference, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods.

Advance taxes and provisions for current income taxes are presented in the balance sheet after off-setting advance taxes paid.

i) Inventories:

Finished Goods are valued at cost or market value whichever is less. Packing material is valued at cost.

j) Provisions, Contingent Liabilities and Contingent Assets:

A provision is recognised when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (excluding retirement benefits and compensated absences) are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates. Contingent liabilities are not recognised in the financial statements. A contingent asset is neither recognised nor disclosed in the financial statements.

k) Earnings per share:

The company reports basic and diluted earnings per share in accordance with Accounting Standard (AS-20) on Earning per share issued by ICAI. Basic earnings per equity share is computed by dividing net income by weighted average number of equity shares outstanding for the period. Diluted earnings per equity share is computed by dividing net income by the weighted average number of equity shares outstanding including shares pending allotment.

l) SMC:

The Company is a Small and Medium Sized Company (SMC) as defined in Rule 2 e of Companies Accounting Standards Rules 2021. Accordingly, the company has complied with the Accounting Standards as applicable to a Small and Medium Sized Company (Except that Cash Flow Statement has been prepared as applicable to a company which is not a Small company as per the provisions of Section 2(85) of the Companies Act, 2013 where applicable.



SHINTO ORGANICS PRIVATE LIMITED (FORMERLY KNOWN AS SHINTO BIOTEC LIMITED)

3 SHARE CAPITAL

Particulars Particulars	AS AT 31ST MARCH, 2023	AS AT 31ST MARCH, 2022
Authorised Share Capital a) 2,50,000 (Previous year 2,50,000) Equity Shares of `10/- Each	25,000.00	25,000.00
	25,000.00	25,000.00
Issued, Subscribed & Paid up: a) 2,50,000 (Previous year 2,50,000) Equity Shares of `10/- Each fully paid	25,000.00	25,000.00
Total	25,000.00	25,000.00

3.1 The details of Shareholders holding more than 5% of the aggregate shares in the Company.

Name of the Share holders	AS AT 31ST MA	AS AT 31ST MARCH, 2023		1ARCH, 2022
	No. of shares	% held	No. of shares	% held
Harsh Gulati	57,300	22.92%	57,300	22.92%
Sumit Juneja	117,600	47.04%	117,600	47.04%
Usha Gulati	74,600	29.84%	74,600	29.84%

3.2 The Reconciliation of the number of shares

Particulars	AS AT 31ST MARCH, 2023 No. of shares	AS AT 31ST MARCH, 2022 No. of shares
Numbers of Shares at the beginning of the year Add: Numbers of shares issued during the year	250,000	250,000
Equity Shares at the end of the year Total	250,000	250,000

3.3 Shares held by promoters at the end of the year

		AS AT	AS AT 31ST MARCH, 2023			AS AT 31ST MARCH, 2022		
Sno.	Promoter Name	No. of Shares	% of Total Shares	% Change During The Year	No. of Shares	% of Total Shares	% Change During The Year	
1 Harsh	Gulati	57,300	22.92%	No Change	57,300	22.92%	No Change	
2 Usha G	Gulati	74,600	29.84%	No Change	74,600	29.84%	No Change	
3 Ashish	Gulati	100	0.04%	No Change	100	0.04%	No Change	

4 RESERVES & SURPLUS

Partio	culars	AS AT 31ST MARCH, 2023	AS AT 31ST MARCH, 1021
(a)	Share Premium	132,551.26	132,551.26
(b)	Surplus/(Deficit) in statement of profit & loss Opening Balance Add: Profit/(Loss) for the year	116,875.02 3,786.71	106,866.57 10,008.45
	Less: Previous Year adjustments	42.50	
	2005 F F C F C G G G G G G G G G G G G G G G	120,619.23	116,875.02
	Total	253,170.49	249,426.28

5 LONG TERM BORROWINGS

Particulars	AS AT 31ST MARCH, 2023	AS AT 31ST MARCH, 2022
Unsecured (a) HDFC LOAN A/C-LAP (85555495) Less - Current Maturities	106,257.61 9,550.16	115,150.66 8,892.98
Total	96,707.46	106,257.68

The loan is against the personal property of director



HORT TERM BORROWINGS		AS AT 31ST MARCH, 2023	AS AT 31ST MARCH, 2022
Particulars			
Secured			
a)			p
Unsecured		9,550.16	8,892.9
(b) Current maturities of long-term debt*	5	3,330.12	
	Total	9,550.16	8,892.

The cash credit limits are secured against stock, debtors and all current assets of company and guranteed by directors.

TRADE PAYABLES		AS AT 31ST	AS AT 31ST MARCH, 2022
Particulars		MARCH, 2023	MARCH, 2022
 (a) Total outstanding dues of micro enterprises and small enterprises (b) Total outstanding dues of creditors other than micro enterprises and small enterprises 		220,094.41	
Y=2	Total	220,094.41	244,277.90

Trade Payables Ageing Schedule (As at 3	Outstanding	for following	periods from du	ue date of	Total
Particulars	Less than 1 Years	1-2 Years	2-3 Years	More than 3 Years	
(i) MSME (ii) Others (iii) Disputed dues – MSME	219,839.53	254.88	-	-	220,094.41
(iv)Disputed dues - Others Total Trade Payables	219,839.53	254.88		-	220,094.41

Trade Payables Ageing Schedule (As at 3	Outstanding	for following	periods from due	e date of	Total
Particulars	Less than 1 Years	1-2 Years	2-3 Years	More than 3 Years	
(i) MSME (ii) Others (iii) Disputed dues – MSME	165,338.37	-	78,939.53	-	244,277.90
(iv)Disputed dues - Others Total Trade Payables	165,338.37	-	78,939.53	-	244,277.9

OTHER CURRENT LIABILITIES	AS AT 31S	
Particulars	MARCH, 20	23 MARCH, 2022
(a) Other payables (b) Advances from customers	7,684 51,493	
(c) Cheque Issued But not cleared	Total 59,177	.62 8,721.09

SHORT TERM PROVISIONS	AS AT 31S	
n_utaulare	MARCH, 20	23 MARCH, 2022
Particulars	1,419	.86 3,383.21
Provision for Income Tax	1,238	3,383.21
Less : Advance Tax	181	58
Less: TCS		
Less : Mat Credit	Total	.00
Less : Mat Credit	Total	.00

SHINTO ORGANICS PRIVATE LIMITED PROPERTY, PLANT & EQUIPMENTS SCHEDULE FOR THE YEAR AS ON 31.03.2023

					TANGIE	TANGIBLE ASSETS					
			GROSS BLOCI	CK			DEPRECIATION	NOI		NET BLOCK	LOCK
PARTICULARS	RATE	AS ON	ADDITION	SALE/	ASON	UPTO THE END	FOR THE	WRITTEN	TOTAL	AS ON	AS ON
		01.04.2022		ADJUST.	31.03.2023	OF PREVIOUS YR.	YEAR	BACK		31.03.2023	31.03.2022
Plant & Machinery		5,315.65			5,315.65	2,358.74	348.85	,	2,707.59	2,608.06	2,956.91
Electrical Equipments		1,728.84			1,728.84	876.40	164.26		1,040.67	688.17	852.44
Car		55,780.16			55,780.16	13,877.76	6,677.52		20,555.28	35,224.88	41,902.40
Mobile		5,139.03			5,139.03	4,574.64	192.03	,	4,766.67	372.36	564.39
Furniture & Fixture		2,071.65			2,071.65	1,281.84	191.27	٠	1,473.11	598.54	789.81
Computer		12,316.05			12,316.05	10,668.65	632.81	1	11,301.46	1,014.59	1,647.40
Water Cooler		178.50			178.50	169.57			169.57	8.93	8.93
Total		82,529.88			82,529.88	33,807.60	8,206.75	٠	42,014.34	40,515.53	48,722.28
Previous Year Figures		82,294.88	235.00		82,529.88	24,921.52	8,886.07	1	33,807.60	48,722.28	57,373.35
	-			The state of the s	Charles the Country of the Country o		The second name of the second na				



NOTE NO -9

AS AT 31ST MARCH, 2023	AS AT 31ST MARCH, 2022
235,984.26	203,861.96
235,984.26	203,861.9
	MARCH, 2023 235,984.26

Note:- Mode of Valuation

Trading Goods stock are valued at Lower of cost & net realisable value. The costs are based on 'First -in-First-out' Method.

12 TRADE RECEIVABLES

TRADE RECEIVABLES	AS AT 31ST	AS AT CIST
Particulars	MARCH, 2023	MARCH, 2022
(a) Trade Receivables considered good - Secured (b) Trade Receivables considered good - Unsecured (c) Trade Receivables which have significant increase in Credit Risk	376,465.33 - -	372,851.12 - -
(d) Trade Receivables - credit impaired.	376,465.33	372,851.12
Total		

Trade Receivables Ageing Schedule (As at 31st March Particulars	Outstanding fo	or following pe	eriods from due d	ate of payment		TOTAL
Particulars	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	TOTAL
(i) Trade Receivables considered good - Secured (ii) Trade Receivables considered good - Unsecured (iii) Trade Receivables which have significant increase	68,720.96	-	94.76	307,649.61	-	376,465.33
(iv) Trade Receivables - credit impaired. Total Trade Payables	68,720.96		94.76	307,649.61	-	376,465.33

Trade Receivables Ageing Schedule (As at 31st March	Outstanding fo	or following pe	eriods from due d	ate of payment		TOTAL
Particulars		6 months - 1 year	1-2 years	2-3 years	More than 3 years	TOTAL
(i) Trade Receivables considered good - Secured (ii) Trade Receivables considered good - Unsecured (iii) Trade Receivables which have significant increase	55,795.44	3,318.07	313,737.61	-	-	372,851.12
(iv) Trade Receivables - credit impaired.	55,795.44	3.318.07	313,737.61		-	372,851.1

13 CASH AND CASH EQUIVALENT

- [CASH AND CASH EQUIVALENT		RCH, 2023	AS AT 31ST MARCH, 2022
- 1	Particulars	MIA	RCH, 2023	WARCH, ZOZZ
1			1,992.00	2,914.95
- 1	(a) Cash in hand & at imprest		2,650.80	6,882.83
	(b) Union Bank of India C/C	Total	4,642.81	9,797.78
- 1				

14 SHORT TERM LOANS & ADVANCES

SHORT TERM LOANS & ADVANCES	AS AT 31ST	AS AT 31ST MARCH, 2022
Particulars	MARCH, 2023	WARCH, ZOZZ
(a) Loans Receivables considered good - Secured		
(b) Loans Receivables considered good - Unsecured	395.35	289.69
- Advances recoverable in cash or in kind or for value to be received	68.21	105.87
- Prepaid Expenses	5,392.79	6,857.66
- Balance with revenue authorities	-	-
(c) Loans Receivables which have significant increase in Credit Risk;	-	-
(d) Loans Receivables - credit impaired Total	5,856.35	7,253.22



SHINTO ORGANICS PRIVATE LIMITED (FORMERLY KNOWN AS SHINTO BIOTEC LIMITED)

15 REVENUE FORM OPERATIONS

Particulars Particulars	For the year as on 31st March , 2023	For the year as on 31st March, 2022
Sale of Products	566,937.05	506,229.28
Total	566,937.05	506,229.28

16 OTHER INCOME

Particulars	For the year as on 31st March, 2023	For the year as on 31st March, 2022
(a) Interest on Income Tax Refund (b) Inventory charges (Packing Material)	87.10 35.00	146.50
(b) Inventory charges (Facking Material) Total	122.10	146.50

17 PURCHASES OF GOODS

Particulars	For the year as on 31st March , 2023	For the year as on 31st March, 2022	
Purchase of Goods Add:- Freight inward	463,797.28 430.40		
Total	464,227.68	365,827.01	

18 CHANGE IN INVENTORY OF GOODS

Particulars	For the year as on 31st March , 2023	For the year as on 31st March, 2022
Opening Balance	203,861.96	199,485.71
Less:- Closing Balance	235,984.26	203,861.96
Net Increase/ Decrease in Goods	(32,122.30)	(4,376.25)

19 EMPLOYEE BENEFITS EXPENSES

Particulars		For the year as on 31st March, 2023	For the year as on 31st March, 2022
Directors Remuneration Salaries, Wages and Bonus Staff Welfare		48,000.00 26,639.23 890.52	48,000.00 24,579.46 65.03
	Total	75,529.75	72,644.49

20 FINANCIAL COST

Particulars		For the year as on 31st March, 2023	For the year as on 31st March, 2022	
Bank Charges Interest		162.30 7,945.59	481.20 8,362.38	
	Total	8,107.89	8,843.58	

DEPRECIATION & AMORTISATION	For the year as on	For the year as on	
Particulars	31st March , 2023	31st March , 2022	
Depreciation	8,206.75	8,886.07	
Tota	8,206.75	8,886.07	



22 OTHER EXPENSES

Parativity.		For the year as on	For the year as on
Particulars		31st March , 2023	31st March , 2022
Direct Expense			
Cylinder/Plate Charges		1,396.00	705.10
Cylinder/Plate Charges		1,396.00	705.10
Administrative Expenses			
Audit Fees		750.00	750.00
Electricity & Water Charges		1,557.56	2,293.60
Insurance Charges (Vehicle)		310.81	649.52
Interest on Income Tax/TDS		-	5.78
Legal & Professional Expenses		563.00	488.00
Loan Processing Charges		-	212.40
GST Late Fee		528.00	
Office Expenses		-	171.10
Freight inward- RCM		1,506.98	-
Festival Exp.		987.67	
Printing & Stationery		189.77	77.80
Postage & Courier		3,665.06	3,423.91
Rate, Fees & Taxes		-	777.21
- Computer			66.00
- Others		106.50	177.73
Telephone Expenses		628.64	689.92
Tour & Travelling Expenses		3,004.23	2,773.48
Misc. Expenses		70.83	110.87
Vehicle Running & Maintenance		5,202.40	5,048.12
Software Upgradation		90.00	90.00
Rate difference/breakerage/round off		9.36	573.97
Selling & Distribution Expenses			
Advertisement & Publicity		_	9.74
Discount			208.37
GST Expense		12,426.80	16,215.02
Bad Debt			289.74
Labour Charges		_	10.00
Business Promotion		634.16	1,222.10
Food & Beverages Exp.		796.29	_,
Freight Outwards		3,360.29	3,834.57
Packing Material		264.75	217.96
i dennig material	Total	38,049.09	41,092.00



SHINTO ORGANICS PRIVATE LIMITED (FORMERLY KNOWN AS SHINTO BIOTEC LIMITED)

23 NOTES TO ACCOUNTS

a) Related party disclosures

As per AS-18 'Related Party Disclosures' issued by ICAI the disclosures of transactions with related concerns are as follow:-

Particulars	Name
Key Managment Bersennel	Harsh Gulati (Managing Director)
Key Managment Personnel	Usha Gulati (Whole Time Director)
Related Concerns	Astonea Labs Private Limited

Name	Relation	Nature of Transactions	Amount (`00)	
ACTONICA LARC PRIMATE LIMITER	DELATED CONCERN	PURCHASES	156,714.76	
ASTONEA LABS PRIVATE LIMITED	RELATED CONCERN	SALES 26,719		
HARSH GULATI	MG. DIRECTOR	SALARY	24,000.00	
USHA GULATI	WHOLE TIME DIRECTOR	SALARY	24,000.00	

b)	Earning Per Share	Rs.	Rs.
	As per AS 20 of ICAI the EPS is worked out as under:	24 02 2022	31.03.2022
	N. 18 Charles to the charles and the Charles	31.03.2023 378,671	1,000,845
	Net Profit available to shareholders as per accounts (')	250,000	250,000
	Weighted average number of shares	1.51	4.00
	Earning per share- Basic and diluted (')	10.00	10.00
	Face value per equity share (`)	10.00	10.00
c)	Auditor's Remuneration	31.03.2023	31.03.2022
٠,	Addition 3 Herinante Indiana.	Rs. (00)	Rs. (00)
	Audit of financial statements	750.00	750.00
	Certifications	-	29.50
d)	Deferred Tax Calculation		
	Deferred tax is calculated as per AS-22 issued by ICAI as under:		
		Rs. (00)	Rs. (00)
	WDV as per Companies Act (A)	40,515.53	48,722.28
	WDV as per Income Tax Act (B)	41,452.68	49,078.17
	Timing Difference (B-A)	937.14	-355.89
	Closing Deferred Tax Assets	235.86	89.57
	Opening Deferred Tax Assets	89.57	156.79
	Deferred Tax Income	146.29	67.22
e)	Contingent Liabilities Not Provided for in respect of:		24 02 2022
		31.03.2023	31.03.2022
		Rs. (00)	Rs. (00) NIL
	i) Bank Guarantee outstanding.	NIL NIL	NIL
	ii) Claim against the Company not acknowledged as debts	NIL	NIL
	iii) Estimated amount of contracts remaining to be executed on capital account net after	NIL	NIL
	advance	200	****
	iv) Unexpired letter of credit	NIL	NIL
f)	Information on Transactions in Foreign Exchange	AUI	NIL
	Foreign currency expenditure	NIL NIL	NIL
	Foreign currency income	NIL	NIL
-1	Consumption of Raw Materials and Stores etc.		
g)	Raw Material Consumed:		
	- Imported	NIL	NIL
	- Indigenous	NIL	NIL
	- Indigenous		
	Spare Parts and Components Consumed:		
	- Imported	NIL	NIL
	- Indigenous	NIL	NIL

h) Employee Retirement Benefits

The company has less than 10 employees, the gratuity provisions are not applicable as per Payment of gratuity Act. Other benefits are accounted for on accrual basis.

i) Segment Reporting

As per AS-17 Segment Reporting issued by ICAI is not applicable to the company, since the company is only dealing in wholesale trading which is considered as one segment.

j) In the opinion of the management and best of their knowledge and belief the value on realization of loans & advances and other current assets in the ordinary course of business will not be less than the amount at which they are stated in Balance Sheet and provisions for all known liabilities have been made.



- k) At year end the management verified & valued the stocks including literature & visulades & is relied upon and is appended, forming part of Auditor's Report.
- l) Disclosures under Micro, Small and Medium Enterprises Development Act, 2006 (27 of 2006) ("MSMD Act, 2006"):

The mannagement has not provided the details in respect to micro small and medium enterprises as required under statutory provisions. According to non availability of records as required to such identification, the disclosures in respect to Micro, Small and Medium Enterprises Development (MSMED) Act, 2006 is

m) Sales, Purchase & Stock of Current year are inclusive of Custom Duty & GST and are net of returns to make the financial statement in accordance to ICDS issued by Income Tax Department. Further, Sales and purchases are subject to reconciliation with GST returns.

Particulars	As per books (Rs. (00)	Output/Input tax ('00) Total as per Fina statement ('0	
SALE OF GOODS	499,596.22	67,340.83	566,937.05
TOTAL	499,596.22	67,340.83	566,937.05
PURCHASE OF GOODS	407,410.02	56,037.25	463,447.26
TOTAL	407,410.02	56,037.25	
GST EXPENSE		11,303.58	11,303.58

- n) As per information & explanation given to us, Sundry Creditors do not include any outstanding due to MSME undertaking.
- o) About 40% outstanding balances as at 31st March 2023 in respect of Unsecured Loans, Sundry Debtors, Sundry Creditors, Loans and Advances are subject to confirmation and reconciliation.
- p) The financial statement for the year has been prepared by Rounding off to Hundred in compliance with Schedule III of the Companies Act, 2013.
- q) The previous year's figures have been reworked, regrouped, rearranged and reclassified, where-ever deemed necessary, in order to make them comparable with the current year's figures except sales& purcahses which are exclusive of taxes as compared to current years figures being inclusive of taxes as detailed in point number "M" above.
- r) Ratio Analysis

S.N			1			
0.	1	Formula	2023	2022	Change %	Explanation
1	CURRENT RATIO (Times) CURRENT ASSETS CURRENT LIABILITIES	CURRENT ASSETS CURRENT LIABILITIES	2.16 622,949 288,822	651,403		FOR CHANGE IN THE BASIS
2	DEBT-EQUITY RATIO(Times) LONG TERM DEBT	LONG TERM DEBTS SHAREHOLDER'S EQUITY	0.38	0.42	-8.92%	
1	SHAREHOLDER'S EQUITY	1	277,935	274,337		
3	DEBT SERVICE COVERAGE RATIO(Times) Earnings	EARNINGS AVAILABLE FOR DEBT SERVICE TOTAL DEBT SERVICE	1.26	1.82	-30.92%	FOR CHANGE IN THE BASIS
	Debt Service		21,213	30,707		
\vdash	Debt Service		16,839	16,839		
4	RETURN ON EQUITY RATIO(%)	PROFIT AFTER TAX AVG. EQUITY SHAREHOLDER'S FUND	1.37%	3.72%	-63%	FOR CHANGE IN THE
	NET EARNINGS		3,787	10,008	-	BASIS
	AVERAGE SHAREHOLDER'S EQUITY		276,136	269,299		
5	TRADE RECEIVABLES TURNOVER RATIO(Times)	SALES AVERAGE TRADE RECEIVABLE	1.41	1.15	22%	
	SALES	AVERAGE TRADE RECEIVABLE	566,937	506,229		
	AVERAGE DEBTORS		403,478	438,691		
	TRADE PAYABLES TURNOVER	TOTAL PURCHASE				
6	RATIO(Times)		2.00	1.43	39%	FOR CHANGE IN THE
	PURCHASES	AVERAGE TRADE PAYABLE	464227.6825	365827.0088		BASIS
	TRADE PAYABLES		232,186	255,022		
	NET WORKING CAPITAL TURNOVER	TOTAL SALES				
	RATIO(%)	AVERAGE WORKING CAPITAL	1.70	1.53	11%	FOR CHANGE IN THE BASIS
	SALES		566,937	506,229		
	NET WORKING CAPITAL		334,127	331,872		
	NET PROFIT RATIO(%)	PAT	0.01	0.02	-66%	
8		NET SALES	3102	3.02	3373	FOR CHANGE IN THE
	PROFIT AFTER TAX		3,787	10,008		BASIS
	NET SALES		566,937	506,229		



9	RETURN ON CAPITAL EMPLOYED(%) EBIT CAPITAL EMPLOYED	EBIT CAPITAL EMPLOYED	3.38% 13,006 384,664	5.60% 21,821	-40%	FOR CHANGE IN THE BASIS
10	INVENTORY TURNOVER RATIO SALES AVERAGE INVENTORY	SALES AVERAGE INVENTORY	257.79% 566,937 219,923	389,667 251.01% 506,229 201,674	3%	
	RETURN ON INVESTMENT(%) INCOME EARNED FROM INVESTMENT COST OF INVESTMENT	INVESTMENT COST OF INVESTMENT			NA	

Other statutory information

- (i) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Group for holding any Benami property.
- (ii) The Company does not have any transactions with companies struck off.
- (iii) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- (iv) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (v) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (vi) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- (vii) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Group shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,
- (viii) The Company has not any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.
- (ix) The provisions of Section 135 relating to Corporate Social Responsibility (CSR) does not apply to company for the year under consideration.

Note 1 to 23 forms an integral part of Balance Sheet.

For Avnish Sharma & Associates

Chartered Accountants FRN - 009398N

CCOUNTANTS MEGHA GOEL M. NO. 529746. (Partner)

UDIN: 23529746BHADW18839

Dated: 07.07.2023

For & on behalf of the Board SHINTO ORGANICS PRIVATE LIMITED

HARSH GULATI MG. DIRECTOR DIN: 00986687

USHA GULATI DIRECTOR DIN: 00986683

SHINTO ORGANICS PRIVATE LIMITED (FORMERLY KNOWN AS SHINTO BIOTEC LIMITED)

Particulars	AS AT 31ST MARCH, 2023	AS AT 31ST MARCH 2022
Other Payables:		
Audit Fees Payable	750.00	693.7
Credit Card - SBI	37.70	033.7
Credit Card - UBI	41.05	-
Credit Card - HDFC Bank	111.63	
GST Payable	462.49	
Legal & Professional Expense Payable	418.75	-
Salary Payable	1,800.00	550.0
Director Salary Payable		1,920.0
TDS Payable	3,023.25	3,186.4
Electricity Charges Payable	1,039.57	915.4
creative charges rayable		37.05
	7,684.44	7,302.73
Advance from customers		
ASHA ENTERPRISES DHANBAD	0.60	
CHEMIST INDIA LIMITED HARYANA	8.63	•
Dr Ruhul Amin BIHAR	50,433.02	*
	14.53	*
DR. V.K JHA MUZAFFARPUR	4.48	-
HARE KRISHNA MEDICOS KAPURTHALA	6.42	•
HOLLINGER PHARMACEUTICALS CD JAIPUR	246.40	-
AISWAL MEDICAL BALRAMPUR	4.00	-
CERYX PHARMACEUTICALS PVT LTD JAMMU	160.00	-
KRISHNA ENTERPRISES INDORE	97.29	7.
MEDIPOINT PHARMA MAHARASHTRA	80.00	
MEGHALAYA ENT. & DRUGS CD SHILLONG	12.91	-
IEW CHIRAG MEDICAL STORE UTTAR PRADESH	2.87	
ATEL ENTERPRISES RAIPUR	9.88	-
AWAN MEDICAL STORE KUSHINAGAR	31.91	-
INNACLE PHARMA TNT KERELA	47.72	-
IDDHI VINAYAK PHARMA TNT KOTA	7.74	-
UHA MEIDCAL SOLAPUR	8.29	
HIELD PHARMA THANE	40.00	
HREE SAINATH MEDICALS SURAT	56.06	
MA ENTERPRISE JALPAIGURI	164.64	
INAYAK ENTERPRISES TNT AURANGABAD	17.00	
RUDHI PHARMA TNT UDIPI	39.39	
HALLA MEDICOSE	- 33.33	20.00
ANUMANT DRUG STORE		47.38
AIN MEDICOS	5	10.69
AVAN TRADERS		
		36.11
	51,493.18	114.18

Particulars	AS AT 31ST MARCH, 2023	AS AT 31ST MARCH, 2022
Short Term Loans & Advances:		
Advances recoverable in cash or in kind		
Credit Card- Yes Bank	395.35	
Cheque Deposited But Not Cleared	-	289.69
	395.35	289 .69
Balance with revenue authorities		
GST Input	1,784.34	3,688.37
Water Charges - Advance	846.73	954.22
Advance Tax	2,761.72	1,616.79
Tax Refundable (FY 2021-22)	-	154.70
Tax Refundable (FY 2020-21)	-	443.58
	5,392.79	6,857.66



SHINTO ORGANICS PRIVATE LIMITED (FORMERLY KNOWN AS SHINTO BIOTEC LIMITED) Notes to Balance Sheet as at March 31, 2023

			TRAC	TRADE PAYABLES						
Particulars	AS AT 31ST MARCH 2023	Less than 1 year	1-2 years	2-3 years	More than 3	AS AT 31ST	Less than 1 year	1-2 years	2-3 years	More than 3
A R ENTERPRISES RADDI	254 00				years	MARCH, 2022				Vears
Ametrical colors and a color of the color of	234.88	,	254.88	ı	•	254.88	254.88	1	,	
Amster Labs	•	•	,		•	617.42	617 42			'
Arvincare	3,613.63	3,613.63	,		,	2 607 94	24:110		í.	1
Astonea Labs Pvt Itd	58,025.44	58.025.44	ï			121 600 22	42,000,34	1		,
AVS NETWORK	•				•	131,005.33	131,689.33	1	i	•
Azot Life Sciences			,			38.57	38.57	1	,	ì
					•	578.03	578.03		,	
bionexy Pharma	863.97	863.97	ï	•	•	•				
euticals	719.73	719.73	,	•	,	•		1	,	ı
G.G.NUTRITIONS BADDI	3,356.33	3,356.33		,		1 585 36	1 585 30		,	1
KAMDHENU AYURVEDIC PHARMACY BADDI	•			,	,	517.30	1,363.36	1	,	
L.V. Lifesciences	•	1		U 3		07./16	277.78		,	
L.V.LIFE SCIENCES BADDI	17 907 50	07 000 71						,	1	•
,	14,092.39	14,892.59	,			19,040.52	19,040.52	1		,
Maricolly and Filalina	3,164.50	3,164.50	ĭ		•	1,203.66	1,203,66	1		
Iviancare Laboratories Pvt Ltd	1	•	j			455.95	455 95	-		
Medics Lifecare	•	,		,	•		00.001	1	i	,
MMG Healthcare	1,899.08	1.899.08	,			00 703 0	, ,	,	,	
MYRTEL CARE AMBALA CITY					•	3,027.38	3,627.38	1	,	1
Park Pharmaceuticals Pharma	42 756 12	17 756 17	,			462.00	462.00	,	ı	,
Doloctor Downs in district	42,730.12	44,730.12	,		•	•		1	,	,
rolestal rowel illudistries	898.13	898.13	1	ī		•	•	,		
Kace Biotech	8,768.01	8,768.01	1	•		•	1			'
RELIANCE JIO INFOCOMLTD	•	1		,			1	,	1	,
RISO FOOD & NUTRACEUTICALS AMBALA	1,629.85	1.629.85	1			, ,,		1	,	,
Shivay Life Science	-	20:0201			,	182.12	182.12	E	,	ı
Sidharth Enterperises	•		ı		•	220.47	570.47	,	,	,
STIMULE KULIDANIA	•		1.	•		•	1	,	,	
SOINIT NTUKANA	•	,	,	•		72.00	72 00			
UHBVN-ELECTRICITY	•	1	1		•	•			'	ı.
Waltz Energy Ltd.	78,939.53	78,939.53	•	,	•	78 030 53		ı	,	
	•		,			2000	•	0	/8,939.53	ř
SERVICES	•	1	,			•	1	٠	1	,
Avnish Sharma & Associates	•			•				,	ī	,
Banbhay Enginers Dyf 1+d			,		•	914.50	914.50			,
They Evim Dy 14d	•	1	1	1	•	62.00	62.00		,	,
ואבע רעווון גאו דומ	•	•	,	•	•	120.00	120.00	e		
Kayms Fiscal Solution Pvt. Ltd.	•	,	1	•	,	198.00	198 00	0 8	,	'
Shambhala IT Solutions		,	1	•	,		100.00	0		1
Siddharth Enterprises	312.62	312.62	,	,		100		0	,	1
		,	1	1		240.92	540.95	ı	,	r
	220 004 41	310 030 53	27.4 00				,		,	
	T4:4C0'077	213,039.33	724.88			244,277.90	165,338.37		78.939.53	



TRADE RECEIVABLES

1973.07 1972.0 1972.0 1973.0		MAPCH 315T	Less than 6	6 months - 1	1-2 years	2-3 years	More than 3 years	AS AT 31ST	Less than 6	6 months - 1	1-2 vears	2-3 years	Moro than 2
Marchelle	TRADE RECEIVABLE	(1) (1) (1) (1) (1) (1) (1) (1)	months	year				MARCH, 2022	months	year		c mod o =	vears
1972 1972	Aarab Pharmaceuticals	464.50	464.50	,	41			0	1				years
Part	Adhunik Pharma & Sales		00:101		,	,		317.34	317.34	1	,		,
1872 1872	Aditya Pharma	•	,	,	, ,				i			,	, ,
1000 1000	Adnish Pharmaceuticals	373.07	373.07	ř				107.01	ć	1		,	1
Part	Agate Medica			,	3.			79./97		187.82	T.	,	,
Color Colo	Abusa Pharma	•		1	,	,			t	,			
Part	Aim Pharma		ć	1		,	,						,
Sept. Leg. Sept.		395.55	395.55	r		,		863.04	863.04	•		•	ı
Section Sect		200.02	200.02	•	,	e	•	572.82	577 87		•	ı	'
Second Color	Alsh Pharma		•	•	,	,	•		717.07	1			1
128.00 1	Alexa Organics Put 1td	2.60	2.60	ı	,	· C	,						ī
manusculticis 2005.20 (883.0)	Aman Medicos	. :		,	ř	ï	6				ı.		ī
Michael Michael 278.28 278.28 153.96 <t< td=""><td>Ambasa Pharma</td><td>639.30</td><td>639.30</td><td></td><td>,</td><td>1</td><td>,</td><td></td><td></td><td></td><td>9</td><td>1</td><td>•</td></t<>	Ambasa Pharma	639.30	639.30		,	1	,				9	1	•
TOTATION OF MATERIAL AND	Anmol Pharmaceuticals			1		,				,			,
Company Variation 46.74	Arina Pharma	278.28	278.28	,		1		153.96	153 96				,
Separation Sep	Asstha Trading Company Variansi	110.93	110.93	•		,	,		06.507	,		,	,
Supplicité 105.57 105.57 105.57 Supplicité 157.22 2.48.38 105.57 105.57 Submittée 4.77.73 4.47.73 4.47.73 1.57.22 1.50.53 Submittée 4.47.73 4.47.73 4.47.73 4.47.73 1.50.53 1.50.53 Submittée 1.60.23 1.60.23 1.60.23 1.60.23 1.20.23 1.20.53	APOLLO MEDICAL AGENCIES SO KHARGONE	46.74	46.74	ı	,		,						
COSE BIKANER 1,972,23 1,972,23 1,972,9 COSE BIKANER 4,972,33 1,972,33 1,972,33 1,972,93 SAL LIMITED HARIYANA 447,73 4,973 1,972,93 2,774,65 2,771,45 SISTAL 612,33 612,33 612,33 612,33 612,33 612,33 612,33 Brimar Sugil (M-I) 133,24 13,24 1,25 1,25 1,24,65 <t< td=""><td>B.D.R drugs & surgicals</td><td>. 070</td><td></td><td>ì</td><td>1</td><td>,</td><td>1</td><td>105.97</td><td>105.97</td><td>,</td><td></td><td>,</td><td></td></t<>	B.D.R drugs & surgicals	. 070		ì	1	,	1	105.97	105.97	,		,	
Applications Appl		1 077 77	248.38		!	,		150.26	150.26	1		, ,	
Application		77.7/6/1	1,972.22		•	1	9	2,721.43	2.721.43	7	1		
ence Pet Lid Barelly 44773 42773 12466 2708 66	LIMITED	07.0	6.20		Ć.					1			
Mode of Secretarian		447.73	CT TAA		,	T.	,	2,769.66	2,769.66	,	1		
Receive Household 10133	Drug Promoters	612.33	617.33	1	1	1	E.	124.65	124.65	,		1	
Media & General CD Pathhani 13.55 3.70 52.88 5	ш	101.93	101.93		, ,			326.87	326.87		,		,
Mode Septement 13.54 13.54 13.54 13.24 13.	GANESA DISTRIBUTORS TNT KANPUR	29.70	29.70	1	ř		,	6	,	•	,		
### Page of the Pa	Govinglyman Madi 8 Control Co. 1	18.55	18.55		,		. ,	27.88	52.88	,	,	ı	1
Activation Act	Gross Vlin Lifecom	13.24	13.24		,	1	,				,	1	t
1.68 1.68 1.68 1.68 1.68 1.68 1.68 1.68 1.68 1.68 1.68 1.68 1.68 1.68 1.68 1.60 1.00.04 1.	HK Agency Patha	4,333.16	4,333.16	,	,		1	4.333.16	,	,	27 000 8		,
10.30	Honey Pharma Distributors TamilNadu	1.68	1.68	,	1		,			, ,	4,333.10	ı	,
TWD behadun 1,500,04 1,500,04 1,500,04 1,000,128 995,62 995,62 TWT Dehnadun 109.74 1,500,04 1,000,128 1,001,28 1,001,28 1,001,28 Indicine Distributo Chakjiadighi 500,00 500,00 500,00 500,00 1,001,28 1,001,28 Indicine Distributo Chakjiadighi 2,264,67 2,264,67 2,264,67 2,264,67 1,001,28 1,001,28 Indicine Distributo Chakjiadighi 2,264,67 2,264,67 2,264,67 2,264,67 2,264,67 2,264,67 2,264,67 2,264,87 2,262,83 2,528,38 2,528,41	J.P. Enterprises	10.30	10.30	1.	,	,	ı		î	1	, ,		
TNTDehradun 109.74 1.05.04 1.00.04 995.62 995.62 Gloid on Distributo Chakjadighi 500.00 500.00 500.00 1.001.28 1.101.28	Jai Maa Vaishnavi Medical Agencies	1.500.04	1 500 04	1	,		,	6	j	.1.	ì		
dictione Distributo Chakjiadighi 500.00 500.00 500.00 1,001.28 1,135.23 1,135.24 1,135.24 1,135.24 1,1	Jain Medicos TNTDehradun	109.74	109 74	1	,			995.62	995.62	;	,	1	
Medical Ag. 1.08 1.08 1,001.28	Joy Gopal Medicine Distributo Chakjiadighi	200.00	500.00	.)	, ,		,		1	Ţ	r		,
1.08 1.08 1.08 1.00	Khodal Krupa Medical Ag.	•		·					t.	,	,	1	,
State Stat	Kalpana cosmetics	1.08	1.08	,		,		1,001.28	1,001.28	1	,	,	,
Y51.74 751.74<	Kohinoor Medical Hall	22.17	22.17	1	,					(1	•	
ABID CAS SURGING ASSEMBLY	Vaa Ambey Agency			,	,	,		751.74	75174		1	ţ	
sedecal Agencies 1,333.00 1,333.00 576.41 576.42 576.41 576.41 576.41 576.42 576.41 576.42 576.41 576.72 576.72 576.72 576.72 576.72 576.72 576.72 576.72 576.72 576.72 576.72 576.72 576.72 576.72 576.72 576.72 576.72 576.72 576.72		2,264.67	2,264.67	1	,	•	,	2,628.38	2.628.38	1 1		,	
redical Agency 130.71 130.71 130.71 1,135.23	Maa Pitambra Agencies	7,323.00	1,323.00	1		í	*	576.41	576.41				
EDICAL AGENCY 253.26 130.71 124.05 124	Mahalaxmi Medical Agency	130 71	, 000	ı	,	1.	•	1,135.23	1,135.23	,	,		
MEDICOR SURGICO 229.49 200.12 A BID 27.14 27.14 27.14 124.05<	MEDICANA MEDICAL AGENCY	263.26	130./1	1	,	,	,		1	í		4	
Marian State	MEENAKSHI MEDICO&SURGICO	229.49	223.20		,	ì	•		(,	,	1	,
ma 2,072.97 2,072.97 2,072.97 free 2,072.97 2,072.97 2,072.97 free 2,072.97 2,072.97 2,072.97 free 2,072.97 2,072.97 2,072.97 free 2,072.97 2,072.97 2,092.46 1,092.46 1,092.46	MOHAMMAD ABID	27.14	27.14	. 11	. ,	r	,		ì	ì	1	,	1
Tima 2,072.97 2,072.97 2,072.97 2,072.97 2,072.97 2,072.97 2,072.97 2,072.97 2,072.97 2,072.97 2,072.97 2,072.97 2,072.97 2,072.97 2,072.97 2,072.97 2,072.97 2,092.46 1,092.4			1	,	. ,				i.		1	,	,
free 2,072.97 2,072.97 1,092.46 1,092.4		94.76	,	ī	94.76			124.05	124.05		1	t	1.
Vedical Store 146.56 146.56 146.56 145.51 1.150.94 1,150.94 1,150.94 1,150.94	Medicino Pharma	2,072.97	2,072.97	1	,	,	, ,	1 002 46	000	94.76	ī	1	,
Armaceuticals 3,154.89 3,154.89 1,150.94 1,150.94 1,150.94 1,150.94 1,150.94 1,150.94 1,150.94 1,150.94 1,150.94	New Green Life	215.31	215.31	,	1		1	1,032.45	1,092.46	,		č	•
3,154.89 3,154.89 1,150.94 1,150.94 1,059.34 1,059.34	vew suisilla Medical Store	146.56	146.56	T.		,			. ,		6)	1	1
3,154,89 - 1,150,94 1,150,94 - 1,150,94 - 1,150,934	lew Drug & Drugs	, 11	r.		,	,	39	183.32	183.32	. ,			,
1,059.34	harma Zone	3,154.89	3,154.89	,	,		,	1,967.82	1,967.82		, ,		1
	-	PC.0014	1,150.94		,		,	1,059.34	1,059.34	7	1		. ,



	-		-	-				-		-		-
K.A. IVIedical Agencies	3,158.77	3,158.77		i	•		2,791.46	2,791.46		1		,
Raju medical agency	1,081.69	1,081.69	•	•	,	,	1,081.70	273.23	808.47	,	,	
Ravi Trader	1,442.86	1,442.86	,	1			340.96	340.96	,	1	,	
RAVPIL PHARMACEUTICALS SO KOLKATA	2,006.26	2,006.26	,	,	,	,	51.86	51.86	1	1		í
R.X Vision	23.90	23.90	•	1	,	,		,	,	1	1	•
Raj Pharmaceuticals Branch no. Rajasthan	3.54	3.54	,		,	,		,	,	1	1	
SM Enterprises	381.41	381.41	,	i	,	•		1	,	,	ı	
S.R.K. Pharma	85.57	85.57	•	•	,	•	360.09	360.09	1		1	,
Sewa Medicose Panipat	3.48	3.48	,	i	,	,		1	1	,	,	ľ
Shree Hari Medical Stores	150.00	150.00	,	,	'	,		1	1	1	ı	,
Shristy Medico	79.30	79.30	1		•	,		×	,	,	,	
Sai Enterprises	372.69	372.69	,	ì	•	•	472.69	1	472.69	,	,	,
Sankat Mochan Agencies	5,175.81	5,175.81	•		,	,	4,867.98	4,867.98	1	1	,	,
Saurabh Pharma	1,034.63	1,034.63	•	ì	,	,	1,141.17	1,141.17		,	1	,
Sharathi Pharma	1,286.53	1,286.53	,		,	:4:	541.38	541.38		,	1	
Shinto Biotec	254.84	254.84	,	ī	,		1,754.84	,		1,754.84		,
Shiva Drug Agency	680.40	680.40	•		,		1,365.67	1,365.67	1		,	,
Shri Chandrasen Remedies	1,642.52	1,642.52	•	ì	1		1,790.45	1,790.45	1	1		
Shubam Enterprises	11,923.76	11,923.76	•	1	•		14,128.16	14,128.16	1	1	ı	,
Shyam Medical Store	2,762.24	2,762.24	•		,	•	1,298.73	1,298.73	į		ı	
SKIN CARE MEDICALS DHARMAPURI	,			î	,		1,511.01	1,511.01	1	,	,	
SONA PHARMA TNT BIHAR SHARIF	•	10		, É	ï	,	1,036.91	1,036.91	,	1	,	,
Shyam Pharmecy	285.60	285.60	•	ī	,			1	. (1	!	,
SUNDRY DEBTORS- OT VIKASNAGAR	307,649.61	•	,		307,649.61		307,649.61	î	ţ	307,649.61	ŧ	
Sunrise Life Sciences	6.83	6.83	•	i	,			,	1	,	1	
Swati Pharma Bhagalpur	2,037.73	2,037.73	1	1	,	i		i		i		,
Tab Pharma	200.02	200.02	•	ï	ì	,	•	1	,	,		
Texon Drug Enterprises	4,217.05	4,217.05	ï	9			3,966.65	3,966.65	1	ï	,	,
Unified Healthcare	3,893.42	3,893.42	1	ć	,	Ÿ	2,409.53	655.20	1,754.33	i		
United Pharma	87.04	87.04	•	1	1	,		ä.	,	1	,	,
V City Hospital	778.88	778.88				ř		i	,	í	1	1
Vishvak Drugs	7.08	7.08			,	1		1	1	1		
	376,465.33	68,720.96	-	94.76	307,649.61		372,851.12	55,795.44	3,318.07	313,737.61	1	

